A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases
Key facts
- Who runs it
- Takeda
- Where
- Chicago, Dallas, Denver, Durham, Great Neck, Irvine, Macon, New Orleans, Normal, St. Petersburg, The Bronx, Tulsa, and Walnut Creek, United StatesSee the 13 sitesAlso in 8 other countries, 19 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 53 people enrolled
- Started
- 4 Nov 2024
- Expected to end
- 16 May 2028
- Type of study
- Interventional
- Treatments tested
- TAK-881
- Koru 24 G HIgH Flo Subcutaneous Safety Needle Set (investigational in the US)
- Record updated
- 8 April 2026
Who can take part
- Age
- 2 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Participants who meet ALL of the following criteria are eligible for this study:
- Participant must have completed Study TAK-881-3001 (NCT05755035)
- Participant or, in the case of minors, legally designated representative(s) is/are willing and able to comply with the requirements of the protocol
- Participant or, in the case of minors, legally designated representative(s) has/have provided informed consent/assent (if applicable), including providing consent for use of the investigational medical device (in US sites only), prior to the initiation of any study procedures
Who cannot take part
- Participant was enrolled in another clinical study involving an investigational product (IP) or investigational device within 30 days prior to screening (with the exception of Study TAK-881-3001 [NCT05755035])
- Participant is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study
- Participant has a serious medical condition such that the participant's safety or medical care would be impacted by participation in this long-term follow-up study
- New medical condition that developed during participation in Study TAK-881-3001 (NCT05755035), that, in the judgment of the investigator, could increase risk to the participant or interfere with the evaluation of TAK-881 and/or conduct of the study
- Participant is a family member or employee of the investigator or the investigator's site staff
- Participants with potential to become pregnant who meet any one of the following criteria:-; Participant has a positive pregnancy test; Participant does not agree to employ a highly effective form of contraception for the duration of the study
- If participant is pregnant or lactating at the time of screening or intends to become pregnant or begin lactating during the study
Where in United States
Also in 8 other countries, 19 sites
- Rush University Medical Center-Allergy/ Immunology CenterChicago, United States
- Allergy Partners of North TexasDallas, United States
- National Jewish Medical and Research CenterDenver, United States
- Duke Asthma Allergy and Airway CenterDurham, United States
- North Shore-Long Island Jewish Health SystemsGreat Neck, United States
- University of California, Irvine Medical Sciences IIrvine, United States
- Central Georgia Infectious Disease ConsultantsMacon, United States
- Louisiana State University Health Science CenterNew Orleans, United States
- Sneeze, Wheeze, & Itch Associates LLCNormal, United States
- University of South FloridaSt. Petersburg, United States
- Montefiore Medical CenterThe Bronx, United States
- Allergy, Asthma and Immunology CenterTulsa, United States
- Allergy & Asthma Clinical ResearchWalnut Creek, United States
About the trial
What the trial wants to find out
The main aim of this study is to learn if TAK-881 is safe and well tolerated during long-term use in adults and children with PIDD who are eligible and completed study TAK-881-3001 (NCT05755035).
Read full original descriptionShow less
The participants will receive the first dose of TAK-881 immunoglobulin (IgG) infusion at the same dosage as the last dose administered in study TAK-881-3001 (NCT05755035). After the first TAK-881 infusion in study TAK-881-3002, the dosing interval (can be adjusted by participant/caregiver) and/or the dose of TAK-881 can be adjusted by the study doctor to every 2, 3 or 4 weeks at scheduled site visits.
Participants will visit the clinic every 12 weeks until the End of Study (EOS) visit.
The group in the trial
- TAK-881Treatment being tested
Epoch 1: Participants who completed study TAK-881-3001 (NCT05755035) and met eligibility criteria will receive TAK-881 using Koru 24 G HlgH Flo subcutaneous (SC) safety needle set (investigational in the US) at the same dose and same treatment interval as at the last infusion in TAK-881-3001 (NCT05755035) at Week 1 and at Weeks 13 and Week 25 of study TAK-881-3002. Epoch 2: Participants with anti-rHuPH20 antibody titer \>=1:160 at any time point during Study TAK-881-3001 (NCT05755035) and/or Study TAK-881-3002 Epoch 1, will continue receiving TAK-881 every 12 weeks for up to Week 121. After the first TAK-881 infusion in study TAK-881-3002, the interval and/or the dose may be adjusted only at scheduled site visits at the investigator's discretion.
Treatment: TAK-881 and Koru 24 G HIgH Flo Subcutaneous Safety Needle Set (investigational in the US)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Long-term Safety and Tolerability of TAK-881 in Subjects With Primary Immunodeficiency Diseases (PIDD)
- Record updated
- 8 April 2026